ID   CH1 [Human ovarian carcinoma]
AC   CVCL_4992
DR   BioSample; SAMN03151886
DR   cancercelllines; CVCL_4992
DR   ChEMBL-Cells; CHEMBL3307620
DR   ChEMBL-Targets; CHEMBL614455
DR   GEO; GSM459735
DR   GEO; GSM711723
DR   GEO; GSM851914
DR   IGRhCellID; CH1
DR   Progenetix; CVCL_4992
DR   PubChem_Cell_line; CVCL_4992
DR   Wikidata; Q54811605
RX   PubMed=1423261;
RX   PubMed=1617660;
RX   PubMed=1892748;
RX   PubMed=2653399;
RX   PubMed=11416159;
RX   PubMed=15677628;
RX   PubMed=22710073;
CC   Problematic cell line: Contaminated. Shown to be a PA-1 derivative (PubMed=22710073).
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00459.
CC   Doubling time: 17 hours (PubMed=2653399).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro316Pro (c.948C>T); ClinVar=VCV000750727; Zygosity=Heterozygous (from parent cell line).
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
ST   Source(s): PubMed=11416159
ST   Amelogenin: X
ST   D21S11: 29,31.2
ST   D8S1179: 14,15
ST   FGA: 24
ST   TH01: 7,9
ST   vWA: 15,17
DI   NCIt; C8114; Ovarian mixed germ cell tumor
DI   ORDO; Orphanet_180234; Mixed germ cell tumor
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0479 ! PA-1
SX   Female
AG   12Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 29
RX   PubMed=1423261;
RA   Mistry P., Kelland L.R., Loh S.Y., Abel G., Murrer B.A., Harrap K.R.;
RT   "Comparison of cellular accumulation and cytotoxicity of cisplatin
RT   with that of tetraplatin and
RT   amminedibutyratodichloro(cyclohexylamine)platinum(IV) (JM221) in human
RT   ovarian carcinoma cell lines.";
RL   Cancer Res. 52:6188-6193(1992).
RX   PubMed=1617660;
RA   Kelland L.R., Mistry P., Abel G., Loh S.Y., O'Neill C.F., Murrer B.A.,
RA   Harrap K.R.;
RT   "Mechanism-related circumvention of acquired
RT   cis-diamminedichloroplatinum(II) resistance using two pairs of human
RT   ovarian carcinoma cell lines by ammine/amine platinum(IV)
RT   dicarboxylates.";
RL   Cancer Res. 52:3857-3864(1992).
RX   PubMed=1892748; DOI=10.1038/bjc.1991.279;
RA   Mistry P., Kelland L.R., Abel G., Sidhar S., Harrap K.R.;
RT   "The relationships between glutathione, glutathione-S-transferase and
RT   cytotoxicity of platinum drugs and melphalan in eight human ovarian
RT   carcinoma cell lines.";
RL   Br. J. Cancer 64:215-220(1991).
RX   PubMed=2653399; DOI=10.1038/bjc.1989.108;
RA   Hills C.A., Kelland L.R., Abel G., Siracky J., Wilson A.P.,
RA   Harrap K.R.;
RT   "Biological properties of ten human ovarian carcinoma cell lines:
RT   calibration in vitro against four platinum complexes.";
RL   Br. J. Cancer 59:527-534(1989).
RX   PubMed=11416159; DOI=10.1073/pnas.121616198;
RA   Masters J.R.W., Thomson J.A., Daly-Burns B., Reid Y.A., Dirks W.G.,
RA   Packer P., Toji L.H., Ohno T., Tanabe H., Arlett C.F., Kelland L.R.,
RA   Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.;
RT   "Short tandem repeat profiling provides an international reference
RT   standard for human cell lines.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001).
RX   PubMed=15677628; DOI=10.1093/carcin/bgi032;
RA   Gorringe K.L., Chin S.-F., Pharoah P.D.P., Staines J.M., Oliveira C.,
RA   Edwards P.A.W., Caldas C.;
RT   "Evidence that both genetic instability and selection contribute to
RT   the accumulation of chromosome alterations in cancer.";
RL   Carcinogenesis 26:923-930(2005).
RX   PubMed=22710073; DOI=10.1016/j.ygyno.2012.06.017;
RA   Korch C.T., Spillman M.A., Jackson T.A., Jacobsen B.M., Murphy S.K.,
RA   Lessey B.A., Jordan V.C., Bradford A.P.;
RT   "DNA profiling analysis of endometrial and ovarian cell lines reveals
RT   misidentification, redundancy and contamination.";
RL   Gynecol. Oncol. 127:241-248(2012).